Matt O'Brien
Stock Analyst at Piper Sandler
(2.12)
# 2,897
Out of 4,914 analysts
179
Total ratings
40.94%
Success rate
-6.78%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMDX TransMedics Group | Reiterates: Overweight | $125 → $145 | $104.83 | +38.32% | 12 | Jun 4, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $100 → $80 | $54.04 | +48.04% | 12 | May 9, 2025 | |
| CVRX CVRx, Inc. | Maintains: Overweight | $20 → $12 | $8.27 | +45.19% | 9 | May 9, 2025 | |
| KIDS OrthoPediatrics | Maintains: Overweight | $40 → $30 | $22.21 | +35.07% | 2 | May 8, 2025 | |
| DXCM DexCom | Maintains: Overweight | $100 → $90 | $89.35 | +0.73% | 11 | May 2, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $13 → $15 | $10.88 | +37.87% | 3 | May 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $36 → $30 | $16.69 | +79.75% | 8 | May 1, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $180 → $165 | $93.76 | +75.98% | 10 | Apr 15, 2025 | |
| KMTS Kestra Medical Technologies | Initiates: Overweight | $27 | $16.54 | +63.24% | 1 | Mar 31, 2025 | |
| TELA TELA Bio | Downgrades: Neutral | $5 → $2 | $1.99 | +0.50% | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $3.47 | +0.86% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $115.49 | +21.22% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $14.66 | +77.35% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $291.49 | +6.35% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $227.15 | +45.28% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $31.73 | +57.58% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $18.57 | -13.84% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $106.47 | +8.01% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $5.74 | +109.06% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $400.57 | +4.85% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 → $140 | $109.20 | +28.21% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $75 | $53.84 | +39.30% | 3 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $92.44 | -2.64% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $80 | $50.29 | +59.08% | 12 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $17.82 | +40.29% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $2.37 | +26.58% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $1.96 | +129.59% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $94.95 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $3.16 | +374.68% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $73.69 | +47.58% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $2.49 | +631.59% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $28.84 | +177.39% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $3.48 | +244.83% | 1 | Jun 24, 2020 |
TransMedics Group
Jun 4, 2025
Reiterates: Overweight
Price Target: $125 → $145
Current: $104.83
Upside: +38.32%
Globus Medical
May 9, 2025
Maintains: Overweight
Price Target: $100 → $80
Current: $54.04
Upside: +48.04%
CVRx, Inc.
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $8.27
Upside: +45.19%
OrthoPediatrics
May 8, 2025
Maintains: Overweight
Price Target: $40 → $30
Current: $22.21
Upside: +35.07%
DexCom
May 2, 2025
Maintains: Overweight
Price Target: $100 → $90
Current: $89.35
Upside: +0.73%
Alphatec Holdings
May 2, 2025
Reiterates: Overweight
Price Target: $13 → $15
Current: $10.88
Upside: +37.87%
Tandem Diabetes Care
May 1, 2025
Maintains: Overweight
Price Target: $36 → $30
Current: $16.69
Upside: +79.75%
Glaukos
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $93.76
Upside: +75.98%
Kestra Medical Technologies
Mar 31, 2025
Initiates: Overweight
Price Target: $27
Current: $16.54
Upside: +63.24%
TELA Bio
Mar 21, 2025
Downgrades: Neutral
Price Target: $5 → $2
Current: $1.99
Upside: +0.50%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $3.47
Upside: +0.86%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $115.49
Upside: +21.22%
Feb 24, 2025
Initiates: Overweight
Price Target: $26
Current: $14.66
Upside: +77.35%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $291.49
Upside: +6.35%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $227.15
Upside: +45.28%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $31.73
Upside: +57.58%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $18.57
Upside: -13.84%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $106.47
Upside: +8.01%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $5.74
Upside: +109.06%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $400.57
Upside: +4.85%
Oct 25, 2024
Reiterates: Overweight
Price Target: $125 → $140
Current: $109.20
Upside: +28.21%
Oct 8, 2024
Reiterates: Overweight
Price Target: $75
Current: $53.84
Upside: +39.30%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $92.44
Upside: -2.64%
Aug 1, 2024
Maintains: Overweight
Price Target: $95 → $80
Current: $50.29
Upside: +59.08%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $17.82
Upside: +40.29%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $2.37
Upside: +26.58%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $1.96
Upside: +129.59%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $94.95
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $3.16
Upside: +374.68%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $73.69
Upside: +47.58%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $2.49
Upside: +631.59%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $28.84
Upside: +177.39%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $3.48
Upside: +244.83%